Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.81 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.81 |
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23075759 | 0.90 | CRBN (1.00) | CRBNDDB1FASN | |
| SCHEMBL23076100 | 0.90 | CRBN (1.00) | CRBNDDB1FASN | |
| SCHEMBL23075751 | 0.90 | CRBN (1.00) | CRBNDDB1FASN | |
| SCHEMBL21496426 | 0.85 | CRBN (0.85) | CRBNDDB1 | |
| SCHEMBL27013321 | 0.84 | CRBN (0.81) | CRBNDDB1FASNLMNACYP3A4 | |
| SCHEMBL21484129 | 0.83 | CRBN (1.00) | CRBNDDB1FASNLMNACYP3A4 | |
| SCHEMBL29347399 | 0.83 | CRBN (0.80) | CRBNDDB1FASN | |
| SCHEMBL23075767 | 0.81 | CRBN (0.71) | CRBNDDB1FASNLMNACYP3A4 | |
| SCHEMBL23067595 | 0.80 | CRBN (1.00) | CRBNDDB1FASNLMNACYP3A4 | |
| SCHEMBL23067568 | 0.80 | CRBN (1.00) | CRBNDDB1FASNLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885FASN 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.